The abstract is read at the publisher; the summary is JClub's.
RNA-targeted therapeutics for chronic hepatitis B are linked to meaningful declines in circulating HBsAg levels, with phase III B-Well data supporting ASO-mediated antigen reduction.
- Why it matters: Nucleos(t)ide analogs suppress HBV replication but do not eliminate cccDNA or integrated HBV DNA, so viral RNA and HBsAg production persist and durable off-treatment control remains hard.
- What they did: The review synthesizes translational pharmacology evidence for siRNAs, ASOs, and CRISPR-Cas13 platforms, including clinical candidates such as JNJ-3989, bepirovirsen, and imdusiran, focusing on transcript-silencing, delivery, and pharmacodynamic endpoints.
- The result: HBsAg reduction alone rarely ensures durable off-treatment control, but it may increase the likelihood of functional cure in biomarker-selected patients and can act as antigen-conditioning within staged strategies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.